Coagulation in hepatobiliary disease

Journal of Veterinary Emergency and Critical Care

Volumn 21, Issue 6, 2011, Pages 589-604

  Kavanagh, Carrie ^a,b   Shaw, Scott ^c   Webster, Cynthia R L ^a  

^a TUFTS UNIVERSITY   (United States)

^b Ocean State Veterinary Specialists   (United States)

^c New England Veterinary Center and Cancer Care   (United States)

Author keywords

Canine; Feline; Hemostasis; Liver

Indexed keywords

ANIMALIA; CANIS FAMILIARIS; FELIDAE;

ANIMAL; ANIMAL DISEASE; BILE DUCT DISEASE; BLOOD; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CAT; CAT DISEASE; DOG; DOG DISEASE; HEMOSTASIS; HUMAN; LIVER DISEASE; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BILE DUCT DISEASES; BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; CAT DISEASES; CATS; DOG DISEASES; DOGS; HEMOSTASIS; HUMANS; LIVER DISEASES;

EID: 84858750540     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2011.00691.x     Document Type: Review

References (191)

1. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010; 148(4):507-521.
2. Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med 2010; 5(1):7-12.
3. Lizarraga AW, Dalia S, Reinert SE, et al. Venous thrombosis in patients with chronic liver disease. Blood Coagul Fibrinolysis 2010; 21(5):431-435.
4. Northup PG, Caldwell SH. New concepts of coagulation and bleeding in liver disease. Intern Emerg Med 2010; 5(1):3-6.
5. Tripodi A, Primignani M, Chantarangkul V, et al. Pro-coagulant imbalance in patients with chronic liver disease. J Hepatol 2010; 53(3):586-587.
6. Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53(2):362-371.
7. Pluta A, Gutkowski K, Hartleb M. Coagulopathy in liver diseases. Adv Med Sci 2010; 55(1):16-21.
8. Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis 2009; 13(1):95-107.
9. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116(6):878-885.
10. McMichael M. Primary hemostasis. J Vet Emerg Crit Care 2005; 15(1):1-8.
11. Smith SA. The cell-based model of coagulation. J Vet Emerg Crit Care 2009; 19(1):3-10.
12. McConnell MF. Overview of haemostasis, In: Day M, Mackin A, Littlewood J. eds. Manual of Canine and Feline Haematology and Transfusion Medicine. 1st edn. Gloucester: British Small Animal Veterinary Association; 2000, pp. 165-171.
13. Licari LG, Kovacic JP. Thrombin physiology and pathophysiology. J Vet Emerg Crit Care 2009; 19(1):11-22.
14. Smith SA. Overview of hemostasis, In: Weiss DJ, Wardrop KJ, eds. Schalm's Veterinary Hematology. 6th edn. Philadelphia: Blackwell Publishing; 2010, pp. 635-653.
15. Colman RW, Marder VJ, Clowes AW, et al. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th edn. Philadelphia: Lipincott, Williams, and Wilkins; 2006
16. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia 2009; 16(1):3-13.
17. DelGuidice LA, White GA. The role of tissue factor and tissue factor pathway inhibitor in health and disease states. J Vet Emerg Crit Care 2009; 19(1):23-39.
18. Hackner SG, Schaer BD. Thrombotic disorders, In: Weiss DJ, Wardrop KJ, eds. Schalm's Veterinary Hematology. 6th edn. Philadelphia: Blackwell Publishing; 2010, pp. 668-677.
19. Brooks MB, DeLaforcade A. Acquired coagulopathies, In: Weiss DJ, Wardrop KJ, eds. Schalm's Veterinary Hematology. 6th ed. Philadelphia: Blackwell Publishing; 2010, pp. 654-660.
20. Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb and Hemos 2008; 34(8):772-778.
21. Borensztajn K, von der Thüsen JH, Peppelenbosch MP, et al. The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm. J Cell Mol Med 2010; 14(1-2):143-153.
22. Northrup PG, Sundraram V, Fallon MB, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008; 6:2-9.
23. Poldervaart JH, Favier RP, Penning LC, et al. Primary hepatitis in dogs: a retrospective review (2002-2006). J Vet Intern Med 2009; 23:72-80.
24. Doige CE, Lester S. Chronic active hepatitis in dogs-A review of 14 cases. J Am Anim Hosp Assoc 1981; 17:725-730.
25. Crawford MA, Schall WD, Jensen RK, et al. Chronic active hepatitis in 26 Doberman pinschers. J Am Vet Med Assoc 1985; 187:1343-1349.
26. Botsch V, Kuchenhoff K, Hartman K, et al. Retrospective study of 871 dogs with thrombocytopenia. Vet Rec 2011; 164:647-651.
27. Prins M, Schellens CJMM, van Leeuwen MW, et al. Coagulation disorders in dogs with hepatic disease. Vet J 2010; 185(2):163-168.
28. Niles JD, Williams JM, Cripps PJ. Hemostatic profiles in 39 dogs with congenital portosystemic shunts. Vet Surg 2001; 30:97-104.
29. Kummeling A, Teske E, Rothuizen J, et al. Coagulation profiles in dogs with congenital portosystemic shunts before and after surgical attenuation. J Vet Intern Med 2006; 20:1319-1326.
30. Dereszynski DM, Center SA, Randolph JF, et al. Clinical and clinicopathologic features of dogs that consumed foodborne hepatotoxic aflatoxins: 72 cases (2005-2006). J Am Vet Med Assoc 2008; 232(9):1329-1337.
31. Shih JL, Keating JH, Freeman LM, et al. Chronic hepatitis in labrador retrievers: clinical presentation and prognostic factors. J Vet Intern Med 2007; 21:33-39.
32. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008; 48(6):1000-1007.
33. Afdhal NH, Esteban R. Introduction: thrombocytopenia in chronic liver disease - treatment implications and novel approaches. Aliment Pharmacol Ther 2007; 26(Suppl 1):1-4.
34. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008; 15(5):473-480.
35. Peck-Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Aliment Pharmacol Ther 2007; 26(Suppl1):21-28.
36. Schoidt FV, Balko J, Schilsky M, et al. Thrombopoietin in acute liver failure. Hepatology 2003; 37(3):558-561.
37. Pereira J, Accatino L, Alfaro J, et al. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 1995; 50:173-178.
38. Witters P, Preson K, Verslype C, et al. Blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmocol Ther 2008; 27:1017-1029.
39. Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther 2007; 26(Suppl 1):5-11.
40. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol 2009; 15(37):4653-4658.
41. Russel KE. Platelet kinetics and laboratory evaluation of thrombocytopenia. In: Weiss DJ, Wardrop KJ, eds. Schalm's Veterinary Hematology. 6th edn. Philadelphia: Blackwell Publishing; 2010, pp. 576-585.
42. Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. J Vet Intern Med 2011; 25(2):169-186.
43. Szatmári V, Rothuizen J, van den Ingh TS, et al. Ultrasonographic findings in dogs with hyperammonemia: 90 cases (2000-2002). J Am Vet Med Assoc 2004; 224(5):717-727.
44. Dunayer EK, Gwaltney-Brant SM. Acute hepatic failure and coagulopathy associated with xylitol ingestion in eight dogs. J Am Vet Med Assoc 2006; 229(7):1113-1117.
45. Rentko VT, Clark N, Ross LA, et al. Canine leptospirosis. A retrospective study of 17 cases. J Vet Intern Med 1992; 6(4):235-244.
46. Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospirosis: 36 cases (1990-1998). J Am Vet Med Assoc 2000; 216(3):371-375.
47. Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome predictors of Leptospira interrogans Australis serogroup infection in dogs: a retrospective study of 20 cases (2001-2004). J Vet Intern Med 2007; 21(1):3-10.
48. Birnbaum N, Barr SC, Center SA, et al. Naturally acquired leptospirosis in 36 dogs: serological and clinicopathological features. J Small Anim Pract 1998; 39(5):231-236.
49. Lisman T, Leebeek F: Hemostatic alterations in liver disease:a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24(4):250-258.
50. Greene CE, Barsanti JA, Jones BD. Disseminated intravascular coagulation complicating aflatoxicosis in dogs. Cornell Vet 1977; 67(1):29-49.
51. Newman SJ, Smith JR, Stenske KA, et al. Aflatoxicosis in nine dogs after exposure to contaminated commercial dog food. J Vet Diagn Invest 2007; 19:168-175.
52. Liptak JM, Dernell WS, Monnet E, et al. Massive hepatocellular carcinoma in dogs: 48 cases (1992-2002). J Am Vet Med Assoc 2004; 225(8):1225-1230.
53. Hwang SJ, Luo JC, Li CH, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10(17):2472-2477.
54. Brown B, Mauldin GE, Armstrong J, et al. Metabolic and hormonal alterations in cats with hepatic lipidosis. J Vet Intern Med 2000; 14(1):20-26.
55. Center SA, Crawford MA, Guida L, et al. A retrospective study of 77 cats with severe hepatic lipidosis: 1975-1990. J Vet Intern Med 1993; 7(6):349-359.
56. Gagne JM, Armstrong J, Weiss D, et al. Clinical features of inflammatory liver disease in cats: 41 cases (1983-1993). J Am Vet Med Assoc 1999; 214(4):513-517.
57. Center SA, Warner K, Cobert J, et al. Proteins invoked by vitamin K absence and clotting times in clinically ill cats. J Vet Intern Med 2000; 14:292-297.
58. Lisciandro SC, Hohenhaus A, Brooks M. Coagulation abnormalities in 22 cats with naturally occurring liver disease. J Vet Intern Med 1998; 12:71-75.
59. Center SA, Elston TH, Rowland PH, et al. Fulminant hepatic failure associated with oral administration of diazepam in 11 cats. J Am Vet Med Assoc 1996; 290(3):618-625.
60. Willis SE, Jackson ML, Meric SM, et al. Whole blood platelet aggregation in dogs with liver disease. Am J Vet Res 1989; 50:1893-1897.
61. Kalbantner K, Meyer-Lindenberg A, Mischke R. Platelet function in dogs with congenital portosystemic shunt. Vet J 2011; 188(2):189-192.
62. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89:273-293.
63. Bosch J, Abraldes JG, Fernández M, et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010; 53(3)558-567.
64. Iwakiri Y, Grisham M, Shah V. Vascular biology and pathobiology of the liver: report of a single-topic symposium. Hepatology 2008; 47:1754-1763.
65. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46(5):927-934.
66. Oda M, Han J, Nakamura M. Endothelial cell dysfunction in microvasculature: relevance to disease processes. Clin Hemor Micro Circ 2000; 20:199-211.
67. Anstee QM, Wright M, Goldin R, et al. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 2009; 13:117-126.
68. Mitchell JA, Ali F, Bailey L, Moreno L, et al. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 2008; 93(1):141-147.
69. Chau TN, Chan YW, Patch D, et al. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998; 43(2):267-271.
70. Yamaguchi M, Gabazza EC, Taguchi O, et al. Decreased protein C activation in patients with fulminant hepatic failure. Scand J Gast 2006; 41(3):331-337.
71. Badylak SF, Van Vleet JF. Alterations of prothrombin time and activated partial thromboplastin time in dogs with hepatic disease. Am J Vet Res 1981; 42(12):2053-2056.
72. Badylak SF Dodds WJ, Van Vleet JF. Plasma coagulation factor abnormalities in dogs with naturally occurring hepatic disease. Am J Vet Res 1983; 44(12):2336-2340.
73. Hoffmann G, van den Ingh TS, Bode P, Rothuizen J. Copper associated chronic hepatitis in Labrador retrievers. J Vet Intern Med 2006; 20(4):856-861.
74. Webb CB, Twedt DC. Acute hepatopathy associated with mitotane administration in a dog. J Am Anim Hosp Assoc 2006; 42(4):298-301.
75. Toulza O, Center SA, Brooks MB, et al. Evaluation of plasma protein C activity for detection of hepatobiliary disease and portosystemic shunting in dogs. J Am Vet Med Assoc 2006; 299:1761-1771.
76. Sevelius E. Diagnosis and prognosis of chronic hepatitis and cirrhosis in dogs. J Small Anim Pract 1995; 36:521-528.
77. Strombeck DR, Miller LM, Harrold D. Effects of corticosteroid treatment on survival time in dogs with chronic hepatitis: 151 cases (1977-1985). J Am Vet Med Assoc 1988; 193(9):1109-1113.
78. Worley DR, Holt DE. Clinical outcome of congenital extrahepatic portosystemic shunt attenuation in dogs aged five years and older: 17 cases (1992-2005). J AmVet Med Assoc 2006; 232(5):722-727.
79. Lipscomb VJ, Jones HJ, Brockman DJ. Complications and long term outcomes of the ligation of congenital portosystemic shunts in 49 cats. Vet Rec 2007; 160(14):465-470.
80. Frankel D, Seim H, MacPhail C, et al. Evaluation of cellophane banding with and without intraoperative attenuation for treatment of congenital extrahepatic portosystemic shunts in dogs. J Am Vet Med Assoc 2006; 228(9):1355-1360.
81. Mehl ML, Kyles AE, Hardie EM, et al. Evaluation of ameroid ring constrictors for treatment for single extrahepatic portosystemic shunts in dogs: 168 cases (1995-2001). J Am Vet Med Assoc 2005; 226(12):2020-2030.
82. Hunt GB, Kummeling A, Tisdall PL, et al. Outcomes of cellophane banding for congenital portosystemic shunts in 106 dogs and 5 cats. Vet Surg 2004; 33(1):25-31.
83. Wolschrijn CF, Mahapokai W, Rothuizen J, et al. Gauged attenuation of congenital portosystemic shunts: results in 160 dogs and 15 cats. Vet Q 2000; 22(2):94-98.
84. Youmans KR, Hunt GB. Cellophane banding for the gradual attenuation of single extrahepatic portosystemic shunts in eleven dogs. Aust Vet J 1998; 76(8):531-537.
85. Bostwick DR, Twedt DC. Intrahepatic and extrahepatic portal venous anomalies in dogs: 52 cases (1982-1992). J Am Vet Med Assoc 1995; 206(8):1181-1185.
86. Murphy ST, Ellison GW, Long M, et al. A comparison of the Ameroid constrictor versus ligation in the surgical management of single extrahepatic portosystemic shunts. J Am Anim Hosp Assoc 2001; 37(4):390-396.
87. Hunt GB, Hughes J. Outcomes after extrahepatic portosystemic shunt ligation in 49 dogs. Aust Vet J 1999; 77(5):303-307.
88. Hottinger HA, Walshaw R, Hauptman JG. Long-term results of complete and partial ligation of congenital portosystemic shunts in dogs. Vet Surg 1995; 24(4):331-336.
89. Smith KR, Bauer M, Monnet E. Portosystemic communications: follow-up of 32 cases. J Small Anim Pract 1995; 36(10):435-440.
90. Komtebedde J, Koblik PD, Breznock EM, et al. Long-term clinical outcome after partial ligation of single extrahepatic vascular anomalies in 20 dogs. Vet Surg 1995; 24(5):379-383.
91. Lawrence D, Bellah JR, Diaz R. Results of surgical management of portosystemic shunts in dogs: 20 cases (1985-1990). J Am Vet Med Assoc 1992; 201(11):1750-1753.
92. Landon BP, Abraham LA, Charles JA. Use of transcolonic portal scintigraphy to evaluate efficacy of cellophane banding of congenital extrahepatic portosystemic shunts in 16 dogs. Aust Vet J 2008; 86:169-179.
93. Winkler JT, Bohling MW, Tillson DM, et al. Portosystemic shunts: diagnosis, prognosis, and treatment of 64 cases (1993-2001). J Am Anim Hosp Assoc 2003; 39(2):169-185.
94. Vogt JC, Krahwinkel DJ Jr, Bright RM, et al. Gradual occlusion of extrahepatic portosystemic shunts in dogs and cats using the ameroid constrictor. Vet Surg 1996; 25(6):495-502.
95. Kummeling A, Van Sluijs FJ, Rothuizen J. Prognostic implications of the degree of shunt narrowing and of the portal vein diameter in dogs with congenital portosystemic shunts. Vet Surg 2004; 33:17-24.
96. Johnson CA, Armstrong PJ, Hauptman JG. Congenital portosystemic shunts in dogs: 46 cases (1979-1886). J Am Vet Med Assoc 1987; 191:1478-1484.
97. Papazoglou LG, Monnet E, Seim HB 3rd. Survival and prognostic indicators for dogs with intrahepatic portosystemic shunts: 32 cases (1990-2000). Vet Surg 2002; 31(6):561-570.
98. White RN, Burton CA, McEvoy FJ. Surgical treatment of intrahepatic portosystemic shunts in 45 dogs. Vet Rec 1998; 142(14):358-365.
99. Liscomb, VJ, Lee KC, Lamb CR, et al. Association of mesenteric portovenographic findings with outcome in cats receiving surgical treatment for single congenital portosystemic shunts. J Am Vet Med Assoc 2009; 234:221-228.
100. Amsellem PM, Seim HB, MacPhail CM, et al. Long-term survival and risk factors associated with biliary surgery in dogs: 34 cases (1999-2004). J Am Vet Med Assoc 2006; 229(9):1451-1457.
101. Pike FS, Berg J, King NW, et al. Gallbladder mucocele in dogs: 30 cases (2000-2002). J Am Vet Med Assoc 2004; 224(10):1615-1622.
102. Church EM. Mathiesen DT. Surgical treatment of 23 dogs with necrotizing cholecystitis. J Am Anim Hosp Assoc 1988; 24:305-310.
103. Holt DE, Mehler S, Mayhew PD, et al. Canine gallbladder infarction: 12 cases (1993-2003). Vet Pathol 2004; 41(4):416-418.
104. Crews LJ, Feeney DA, Jensen CR, et al. Clinical, ultrasonographic, and labratory findings associated with gallbladder disease and rupture in dogs: 45 cases (1997-2007). J Am Vet Med Assoc 2009; 234(3):359-366.
105. Mehler SJ, Mayhew PD, Drobatz KJ, Holt DE. Variables associated with outcome in dogs undergoing extrahepatic biliary surgery: 60 cases (1988-2002). Vet Surg 33(6):644-649.
106. Worley DR, Hottinger HA, Lawrence HJ. Surgical management of gallbladder mucoceles in dogs: 22 cases (1999-2003). J Am Vet Med Assoc 2004; 225(9)1418-1422.
107. Harkin KR, Cowan LA, Andrews GA, et al. Hepatotoxicity of stanozolol in cats. J Am Vet Med Assoc 2000; 217(5):681-684.
108. Mayhew PD, Holt DE, McLear RC. Pathogenesis and outcome of extrahepatic biliary duct obstruction in cats. J Small Anim Pract 2002; 43(6):247-253.
109. Center SA, Baldwin BH, King JM, et al. Hematologic and biochemical abnormalities associated with induced extrahepatic bile duct obstruction in the cat. Am J Vet Res 1983; 44(10):1822-1829.
110. Boute NJ, Mitchell SL, Penninck D, et al. Cholecystoenterostomy for the treatment of extrahepatic biliary tract obstruction in cats: 22 cases (1994-2003). J Am Vet Med Assoc 2006; 9:1376-1382.
111. Stokol T, Brooks M. Diagnosis of DIC in cats: is it time to go back to the basics? J Vet Intern Med 2006; 20:1289-1290.
112. Estrin MA, Wehausen CE, Jessen CR, et al. Disseminated intravascular coagulation in cats. J Vet Intern Med 2006; 20(6):1334-1339.
113. Nelson GL, Andreasen C. The utility of plasma D-dimer to identifiy thromboembolic disease in dogs. J Vet Intern Med 2003; 17:830-834.
114. Ferro D, Celestini A, Viola F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009; 13:21-31.
115. Caldwell ET, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disesase: pathophysiology and critical assessment of current management. Hepatology 2006; 44(4):1042-1046.
116. Wiinberg B, Asger LJ, Johansson PI, et al. Development of a model based scoring system for diagnosis of canine disseminated intravascular coagulation with independent assessment of sensitivity and specificity. Vet J 2010; 185:292-298.
117. Wiinberg B, Jensen AL, Johansson PI, et al. Thromboelastographic evaluation of hemostatic function in dogs with disseminated intravascular coagulation. J Vet Intern Med 2008; 22:357-365.
118. Boisvert AM, Swenson CL, Haines CJ. Serum and plasma latex agglutination tests for detection of fibrin(ogen) degradation products in clinically ill dogs. Vet Clin Pathol 2001; 30(3):133-136.
119. Kuzi S, Segev G, Haruvi E, et al. Plasma antithrombin activity as a diagnostic and prognostic indicator in dogs: a retrospective study. J Vet Intern Med 2010; 24:587-596.
120. Calvaruso V, Maimone S, Gatt A, et al. Coagulation and fibrosis in chronic liver disease. Gut 2008; 57:1722-1727.
121. Papatheodoridis GV, Patch D, Webster GJM, et al. Infection and hemostasis in decompensated cirrhosis: a prospective study using thromboelastography. Hepatology 1999; 29:1085-1090.
122. Rogers CL, O'Toole TE, Keating JH, et al. Portal vein thrombosis in cats: 6 cases (2001-2006). J Vet Intern Med 2008; 22(2):282-287.
123. Roy RG, Post GS, Waters DJ, et al. Portal vein thrombosis as a complication of portosystemic shunt ligation in two dogs. J Am Anim Hosp Assoc 1992; 28:53-58.
124. Diaz Espineira MM, Vink-Nooteoom M, Van den Ingh TS, et al. Thrombosis of the portal vein in a miniature schnauzer. J Small Anim Pract 1999; 40(11):540-543.
125. Van Winkle TJ, Bruce E. Thrombosis of the portal vein in eleven dogs. Vet Pathol 1993; 30(1):28-35.
126. Willard MD, Bailey MQ, Hauptman J, et al. Obstructed portal venous flow and portal vein thrombus in a dog. J Am Vet Med Assoc 1989; 194(10):1449-1451.
127. Valla DC. Thrombosis and anti-coagulation in liver disease. Hepatology 2008; 47:1384-1393.
128. Luyendyk JP, Sullivan BP, Guo GL, et al. Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. Am J Pathol 2010; 176(1):177-186.
129. Sullivan BP, Wang R, Tawfik O, et al. Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies. Toxicol Sci 2010; 115(1):286-294.
130. Shi J, Hao JH, Ren WH, et al. Effects of heparin on liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2003; 9(7):1611-1614.
131. Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003; 52:404-409.
132. Bunch SE, Johnson SE, Cullen JM. Idiopathic noncirrhotic portal hypertension in dogs: 33 cases (1982-1998). J Am Vet Med Assoc 2001; 218(3):392-399.
133. Laurenson MP, Hopper K, Herrera MA, Johnson EG. Concurrent diseases and conditions in dogs with splenic vein thrombosis. J Vet Intern Med 2010; 24(6):1298-1304.
134. Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51(4):682-689.
135. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced function capacity. Hepatology 2006; 44:53-61.
136. Lisman T, Bakhtiari K, Pereboom IT, et al. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010; 52(3):355-361.
137. Hostelle MJ, Geertzen HGM, Straatsburg IH, et al. Factor VIII expression in liver disease. Thromb Haemost 2004; 91:267-275.
138. Lombardi R, Mannucci PM, Seghatchian MJ, et al. Alterations of factor VIII von Willebrand factor in clinical conditions associated with an increase in its plasma concentration. Br J Haematol 1981; 49:61-68.
139. Brazzell JL, Borjesson DL. Evaluation of plasma antithrombin activity and D-dimer concentration in populations of healthy cats, clinically ill cats, and cats with cardiomyopathy. Vet Clin Path 2008; 36(1):79-84.
140. Monroe DM, Hoffman M. The coagulation cascade in cirrhosis. Clin Liver Dis 2009; 13:1-9.
141. Gashen L. Update on hepatobiliary imaging. Vet Clin North Am Small Anim Pract 2009; 39(3):439-467.
142. d'Anjou MA, Penninck D, Cornejo L, et al. Ultrasonographic diagnosis of portosystemic shunting in dogs and cats. Vet Radiol Ultrasound 2004; 45(5):424-437.
143. Zwingenberger AL, Schwarz T. Dual phase CT angiography of the normal canine portal and hepatic vasculature. Vet Radiol Ultrasound 2004; 45(2):117-124.
144. Mai W. Multiphase time resolve contrast enchanced portal MRA in normal dogs. Vet Radiol Ultrasound 2009; 50(1):52-57.
145. Zwingenberger A. CT diagnosis of portosystemic shunts. Vet Clin North Am Small Anim Pract 2009; 39(4):783-792.
146. Bertolini G, Rolla EC, Zotti A, et al. Three-dimensional multislice helical computed tomography techniques for canine extra-hepatic portosystemic shunt assessment. Vet Radiol Ultrasound 2006; 47(5):439-443.
147. Echandi RL, Morandi F, Daniel WT, et al. Comparison of transplenic multidetector CT portography to multidetector CT-angiography in normal dogs. Vet Radiol Ultrasound 2007; 48(1):38-44.
148. Jeong Y, Lim C, Oh S, et al. Three dimensional CT angiography of the canine hepatic vasculature. J Vet Sci 2008; 9(4):407-413.
149. Bruehschwein A, Foltin I, Flatz K, et al. Contrast enhanced magnetic resonance angiography for the diagnosis of portosystemic shunts in 10 dogs. Vet Radiol Ultrasound 2010; 51(2):116-121.
150. Seguin B, Tobias KM, Gavin PR, et al. Use of magnetic resonance angiography for the diagnosis of portosystemic shunts in dogs. Vet Radiol Ultrasound 1999; 40:251-258.
151. Bach AM, Hann LE, Brown KT, et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201:149-154.
152. Saridomichelakis MN, Koutinas CK, Souftas V, et al. Extensive caudal vena cava thrombosis secondary to unilateral renal tubular cell carcinoma in a dog. Small Anim Pract 2004; 45(2):108-112.
153. Tachil J. Relevance of clotting tests in liver disease. Post Grad Med J 2008; 84(990):177-181.
154. Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36:437-441.
155. Reverter JC. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemostasis 2006; 4:717-720.
156. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40:484-488.
157. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67:138-145.
158. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46(4):727-733.
159. Rozanski EA, Drobatz KJ, Hughes D, et al. Thrombotest (PIVKA) test results in 25 dogs with acquired and hereditary coagulopathies. J Vet Emerg Crit Care 1999; 9(2):73-78
160. Kristensen AT, Wiinberg B, Jessen LR, et al. Evaluation of human recombinant tissue factor-activated TEG in 49 dogs with neoplasia. J Vet Intern Med 2008; 22:140-147.
161. Sinnot VB, Otto CM. Use of thromboelastography in dogs with immune-mediated hemolytic anemia: 39 cases (2000-2008). J Vet Emerg Crit Care 2009; 19(5):484-488.
162. Bonnard P, Vitte RL, Barbare JC, et al. Is bleeding time measurement useful for choosing the liver biopsy route? The results of a pragmatic, prospective multicentric study in 219 patients. J Clin Gastroenterol 1999; 29(4):347-349.
163. Sakai M, Watari T, Miura T, et al. Effects of DDAVP administered subcutaneously in dogs with aspirin-induced platelet dysfunction and hemostatic impairment due to chronic liver disease. J Vet Med Sci 2003; 65:83-86.
164. Wang SC, Shieh JF, Chang KY et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc 2010; 42(7):2590-2593
165. Agarwal S, Senzolo M, Melikian C, et al. The prevalence of a heparin-like effect shown on the thromboelastogram in patients undergoing liver transplantation. Liver Transplant 2008; 14(6):855-860.
166. O'Grady JG, Alexander GJ, Hayliar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445.
167. De Gasperi A, Corti A, Mazza E. Acute liver failure: managing coagulopathy and the bleeding diathesis. Transplant Proc 2009; 41:1256-1259.
168. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. AASLD Position Paper. Hepatology 2009; 49:1017-1044.
169. Bigge LA, Brown DJ, PenninckDG. Correlation between coagulation profile findings and bleeding after ultrasound guided biopsies: 434 cases (1993-1996). J Am Anim Hosp Assoc 2001; 37(3):228-233.
170. Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975; 16:617-620.
171. de Boer MT, Christensen MC, Asmussen M, et al. Impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008; 106:32-44.
172. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46(8):1279-1285.
173. Weatherton LK, Streeter EM. Evaluation of fresh frozen plasma administration in dogs with pancreatitis. (1995-2005). J Vet Emerg Crit Care 2009; 19(6):617-622.
174. Castellanos I, Couto CG, Gray TL. Clinical use of blood products in cats: a retrospective study (1997-2000). J Vet Intern Med 2004; 18:529-532.
175. Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management-fresh frozen plasma. Best Pract Res Clin Anaesthesiol 2010; 24(1):51-64.
176. Logan JC, Callan MB, Drew KD, et al. Clinical indications for use of fresh frozen plasma in dogs: 74 dogs (October through December 1999). J Am Vet Med Assoc 2001; 218(9):1449-1455.
177. Snow SJ, Ari Jutkowitz L, Brown AJ. Trends in plasma transfusion at a veterinary teaching hospital: 308 patients (1996-1998 and 2006-2008). J Vet Emerg Crit Care 2010; 20(4):441-445.
178. Jones RM, Moulton CE, Hardy KJ. Central venous pressure and its effect on blood loss during liver resection. Br J Surg 1998; 85(8):1058-1060.
179. Alkozai EM, Lisman T, Porte RJ. Bleeding in liver surgery: prevention and treatment. Clin Liv Dis 2009; 13:145-154.
180. Houston DM, Myers SL. A review of Heinz body anemia in the dog induced by toxins. Vet Hum Toxicol 1993; 35(2):158-161.
181. Polson J, Lee WM. AASLD Position Paper: the management of acute liver failure. Hepatology 2005; 41(5):1179-1197.
182. Callan MB, Oakley DA, Shofer FS, et al. Canine red blood cell transfusion practice. J Am Anim Hosp Assoc 1996; 32(4):303-311.
183. Fanchini M, Montagnana M, Targher G, et al. The use of recombinant factor VIIa in liver diseases. Blood Coagul Fibrinolysis 2008; 19:341-348.
184. Shami V, Caldwell S, Hespenheide E. Recombinant activated factor VII for coagulopathy of fulminant hepatic failure compared with conventional therapy. Liver Transplant 2003; 9:138-143.
185. Sajjad S, Garcia M, Malik A, et al. Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy. Dig Dis Sci 2009; 54(5):1115-1119.
186. Condat B, Pessione F, Denninger MH, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466-470.
187. Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010; 123(2):111-119.
188. Orr DW, Harrison PM, Devlin J, et al. Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long term follow up. Clin Gastro Hepatol 2007; 5(1):80-86.
189. Diquelou A, Barbaste C, Gabaig AM, et al. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200u/kg) administered subcutaneously of intravenously to healthy dogs. Vet Clin Pathol 2005; 34(3):237-242.
190. Mischke R, Grebe S, Jacobs C, et al. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of low molecular weight heparin in healthy dogs. Am J Vet Res 2001; 62(4):595-598.
191. Scott KC, Hansen BD, DeFrancesco TC. Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis. J Vet Emerg Crit Care 2009; 19(1):74-80.